Marked Chart Marked Chart Closed

The Marked Chart Wire · Health

Obesity Drugs

Lilly reports eloralintide phase 2 results at ObesityWeek

Eli Lilly presented phase 2 data for eloralintide, showing 74% of participants reported fewer cravings and 52% less food noise. The company also shared updates on eloraTZP, retatrutide, Zepbound, and Foundayo.

LLY-2.3%

Part of a series: Obesity drug pipeline and access updates

Illustration for the Health desk

The stocks in this story

  1. LLY-2.3%Eli Lilly$1,351

Prices from Based on Thu, Nov 19 close · Opens Fri 9:30 AM ET. Each tile opens the stock's chart and news.

New to this? Read: Reading a stock chart

More Health news

Illustration for the Health desk

Obesity Drugs

Zealand Pharma starts Phase 2 trial for obesity drug combo

Zealand Pharma announced the launch of its Phase 2 ZYNERGY study. The trial assesses the combined use of petrelintide and enicepatide in patients with obesity or overweight.

Biohaven

Biohaven shares phase 1 results for BHV-1530

Biohaven disclosed early trial data for its antibody-drug conjugate BHV-1530. The findings showed that patients with FGFR3-altered cancers experienced shrinkage of tumors and other clinical benefits.

Fast headlines, summarized. Not verified and not advice. Check the full story before you act.